Impact of various options of neoadjuvant chemotherapy on the hormonal status of patients with breast cancer
https://doi.org/10.17650/1994-4098-2010-0-4-24-27
Abstract
Objective: to study hormone balance changes caused by various options of neoadjuvant chemotherapy (CT) in patients with breast cancer (BC).
Materials and methods. Data on 200 patients aged 30 to 65 years with primary BC (Stages IIB-IIIA), who had been treated at the Rostov Cancer Research Institute in 2006 to 2009, served as a material for the study. The levels of steroid hormones of the estrogenic, androgenic, and glucocorticoid series were studied before and after neoadjuvant CT.
Results. When neoadjuvant poly-CT (PCT) was performed on automedia, the levels of total estrogens were almost unchanged; the frac- tions of estrone and estriol also remained stable. Only estradiol levels were recorded to show a certain declining tendency.
There were considerable changes in the expression of all steroid hormones during preoperative systemic PCT.
According o the drug therapy option, significant differences were found in the time course of changes in blood cortisol levels.
Conclusion. Neoadjuvant CT on automedia results in diminished estrogenization irrespective of age and the phase of the menstrual cycle.
About the Authors
Yu. S. Sidorenko
Rostov Cancer Research Institute, Ministry of Health and Social Development of the Russian Federation, Rostov-on-Don
Russian Federation
Russian Federation
O. I. Kit
Rostov Cancer Research Institute, Ministry of Health and Social Development of the Russian Federation, Rostov-on-Don
Russian Federation
Russian Federation
A. E. Lisutin
Rostov Cancer Research Institute, Ministry of Health and Social Development of the Russian Federation, Rostov-on-Don
Russian Federation
Russian Federation
O. M. Semiletkin
Rostov Cancer Research Institute, Ministry of Health and Social Development of the Russian Federation, Rostov-on-Don
Russian Federation
Russian Federation
References
1. Горбунова В.А. Новые платиновые производные. В кн.: Новые цитостатики в лечении злокачественных опухолей. Под ред. В.А. Горбуновой. М., 1998; с. 9–24.
2. Pinedo H.M., Honkoop A.H., Boven E. et al. Improved disease free survival (DFS) of patients with locally advanced breast cancer (LABC) using prolonged dose intensive neoadjuvant doxorubicin (A), cyclophosphamide (C) and GM-CSF. Proc ASCO 1996;15; abstr. 88.
3. Ayash L.J., Elias P., Ibrahim J. et al. High dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 1998;6:1000.
4. Сидоренко Ю.С., Бордюшков Ю.Н. Нетрадиционные методы химиотерапии и механизмы действия. I съезд онкологов стран СНГ. Ч.II. М., 1996.
5. Сидоренко Ю.С. Аутогемохимиотерапия. Ростов н/Д, 2002.
6. Dingemans E., Huts Z., Hartor Kats S.L. Хроматографическое фракционирование нейтральных 17-кетостероидов мочи. J Chimic Endocrin Metab 1952;12(1):66.
7. Камышников В.С. Справочник по клинико-биохимическим исследованиям и лабораторной диагностике. М., 2004; c. 724–7.
8. Дружинина К.В. Хроматографическое разделение кортикостероидов мочи на тонком слое силикагеля КСК-2. Вопр мед хим 1965;11(4):81–7.
9. Савченко О.Н., Степанов Г.С. Фракционное определение эстрогенов в моче не-беременных женщин. Пробл эндокринол 1966;(3):11–7.
Review
For citations:
Sidorenko Yu.S., Kit O.I., Lisutin A.E., Semiletkin O.M. Impact of various options of neoadjuvant chemotherapy on the hormonal status of patients with breast cancer. Tumors of female reproductive system. 2010;(4):24-27. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-4-24-27
Views:
568
Email this article 